European Commission Approves Opdivo® Plus Yervoy® for First-Line Treatment of MSI-H or dMMR mCRC

Deerfield Management to Acquire Singular Genomics for $20 Per Share in All-Cash Deal

EU Approval of Tagrisso Sets New Standard for EGFR-Mutated NSCLC Treatment

Aurobindo Pharma’s Subsidiary CuraTeQ Secures UK Approval for Bevacizumab Biosimilar

SCG Cell Therapy Partners with A*STAR BTI and NATi to Advance RNA-Based Therapeutics

Korea's National Bio Big Data Project: Advancing Precision Medicine with Macrogen and Illumina

GST Exemption Announced for Cancer Treatment Gene Therapy

AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

The Role of Big Data in Precision Medicine

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

OncoHelix and Qualisure Diagnostics Partner to Bring Thyroid GuidePx® Test to Canadian Patients

Home
/
update
/
details

FDA Permits Compassionate Use of Telix's Glioma PET Imaging Agent

NextEdge Admin

01 Aug 2024

1 min 43 sec

Telix Pharmaceuticals has launched an expanded access program in the US to increase the availability of its PET imaging agent TLX101-CDx (18F-floretyrosine or 18F-FET) for patients with advanced glioma. This initiative is part of the company's preparation to file a new drug application for TLX101-CDx in the third quarter, under the US Food and Drug Administration's compassionate use program.

This expanded access allows patients with advanced or recurrent glioma to use TLX101-CDx outside of clinical trials. Telix has utilized TLX101-CDx in clinical trials to identify brain cancer patients suitable for its radiopharmaceutical TLX101 (131I-IPA). Both the imaging agent and the therapeutic target two membrane transport proteins: large amino acid transporter 1 (LAT1) and large amino acid transporter 2 (LAT2).

The program aims to enhance access to TLX101-CDx, which Telix believes could improve diagnosis and imaging-based treatment decisions compared to MRI technology. While guidelines in the US and Europe recommend amino acid PET imaging for glioma patients, the FDA has yet to approve a targeted amino acid PET imaging agent for commercial use.